Paradigm Biocapital Advisors LP - CRINETICS PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
Paradigm Biocapital Advisors LP ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$64,795,638
+157.8%
2,178,737
+56.2%
4.40%
+126.4%
Q2 2023$25,137,936
+38.1%
1,395,002
+23.0%
1.94%
+12.5%
Q1 2023$18,208,539
+11.8%
1,133,782
+27.4%
1.73%
-9.7%
Q4 2022$16,288,922
+59.7%
890,105
+71.4%
1.91%
+40.7%
Q3 2022$10,198,000519,2561.36%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q4 2023
NameSharesValueWeighting ↓
Vivo Capital, LLC 3,375,169$84,379,0007.91%
RA Capital Management 1,875,209$46,880,0002.52%
Perceptive Advisors 2,587,953$64,698,0001.48%
New Leaf Venture Partners, L.L.C. 167,700$4,193,0001.12%
Orbimed Advisors 2,039,282$50,982,0000.79%
Eventide Asset Management 803,839$20,096,0000.61%
Novo Holdings A/S 135,009$3,375,0000.47%
Opaleye Management Inc. 36,000$900,0000.27%
ADAGE CAPITAL PARTNERS GP, L.L.C. 490,000$12,250,0000.03%
Baker Brothers Advisors 132,985$3,325,0000.02%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders